IPO Pipeline: Filings begin to trickle in pre-Labor Day

IPO Boutique keeps apprised of the active pipeline. Currently there are 62 active IPOs in the pipeline as of September 2, 2017. No SPACs or Unit Offerings are included. While the numbers may look diminished, we outlined why “looks may be perceiving” when it comes to the IPO pipeline in this article.

Screen Shot 2017-09-02 at 7.42.10 AM

NEW FILINGS

Company: Secoo Holding Limited
Symbol: SECO
Description: They are Asia’s largest online integrated upscale products and services platform as measured by GMV in 2016, according to the Frost & Sullivan report.
Trade Date: TBD
Underwriter(s): Jefferies
Filed: 8-25-17
Listed Cash Raise: $100 million

Company: Sol-Gel Technologies, Ltd.
Symbol: SLGL
Description: They are a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases
Trade Date: TBD
Underwriter(s): Jefferies, BMO Capital Markets
Co-Manager(s): JMP Securities, Raymond James
Filed: 8-29-17
Listed Cash Raise: $86.25 million

Company: RYB Education, Inc.
Symbol: RYB
Description: They are the largest early childhood education service provider in China, as measured by annual total revenues in 2016, according to the Frost & Sullivan Report.
Trade Date: TBD
Underwriter(s): Credit Suisse, Morgan Stanley
Co-Manager(s): CICC
Filed: 8-30-17
Listed Cash Raise: $100 million

Company: Nightstar Therapeutics Limited
Symbol: NITE
Description: They are a leading clinical-stage gene therapy company focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. v
Trade Date: TBD
Underwriter(s): Jefferies, Leerink Partners, BMO Capital Markets
Co-Manager(s): Wedbush PacGrow, Chardan
Filed: 8-31-17
Listed Cash Raise: $86.25 million

Company:       Deciphera Pharmaceuticals
Symbol:           DCPH
Description:    They are a clinical-stage biopharmaceutical company developing new drugs to improve the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of many cancer therapies.
Trade Date:     TBD
Underwriter(s):  J.P. Morgan, Piper Jaffray
Co-Manager(s): JMP Securities, Nomura
Filed: 9-1-17
Listed Cash Raise: $100 million

 

Company:       Restoration Robotics, Inc.
Symbol:           HAIR
Description:    They are a medical technology company developing and commercializing a robotic device, the ARTAS System, that assists physicians in performing many of the repetitive tasks that are a part of a follicular unit extraction surgery, a type of hair restoration procedure.
Trade Date:     TBD
Underwriter(s):  National Securities Corporation
Co-Manager(s): Roth Capital Partners, Craig-Hallum Capital Group
Filed: 9-1-17
Listed Cash Raise: $28.75 million

 

Company:       Roku, Inc.
Symbol:           ROKU
Description:    They pioneered streaming to the TV. Roku connects users to the streaming content they love, enables content publishers to build and monetize large audiences, and provides advertisers with unique capabilities to engage consumers.
Trade Date:     TBD
Underwriter(s):  Morgan Stanley, Citigroup, Allen & Co., RBC Capital Markets
Co-Manager(s): Needham & Co., Oppenheimer & Co., William Blair
Filed: 9-1-17
Listed Cash Raise: $100 million

 

Company:       Nucana PLC
Symbol:           NCNA
Description:    They are a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines.
Trade Date:     TBD
Underwriter(s):  Citigroup, Jefferies, Cowen
Co-Manager(s): William Blair
Filed: 9-1-17
Listed Cash Raise: $115 million

UPDATED TERMS

Company:       Zai Lab Limited
Symbol:           ZLAB
Description:    They are an innovative biopharmaceutical company based in Shanghai focusing on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the areas of oncology, autoimmune and infectious diseases.
Shares: 5.88 million
Price Range: $16.00-$18.00
Trade Date:     9/20
Underwriter(s):  J.P. Morgan, Citigroup, Leerink Partners
Terms Added: 9-1-17

IPO Pipeline: Filings begin to trickle in pre-Labor Day
Scroll to top
error: Content is protected !!